JNJJanssen Research & Development, LLCRunning, no new patients
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma · Mantle Cell Lymphoma · Follicular Lymphoma · Diffuse Large B-cell Lymphoma · Waldenstrom Macroglobulinemia · Chronic Graft Versus Host Disease
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 539 (final count)
- Started
- Sep 9, 2013
- Main results expected
- Dec 31, 2026
- Fully finished
- Dec 31, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants affected by an adverse event
Measured over: Up to 30 days after the last dose of study drug, or until the start of a subsequent systemic anti-cancer therapy, if earlier
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT01804686 · record last updated 2026-11-03 · checked 2026-11-09 15:42 UTC